The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease. In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.
Study Type
OBSERVATIONAL
Enrollment
1,150
2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels
CHU d'Amiens
Amiens, France
Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: Inclusion
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 6 months
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 12 months
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 12 months
Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 18 months
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU de Besancon
Besançon, France
NOT_YET_RECRUITINGCHU de Bordeaux
Bordeaux, France
NOT_YET_RECRUITINGCHU de Caen
Caen, France
NOT_YET_RECRUITINGCHU de Clermont Ferrand
Clermont-Ferrand, France
NOT_YET_RECRUITINGHopital Henri Mondor
Créteil, France
NOT_YET_RECRUITINGCHU de Dijon
Dijon, France
NOT_YET_RECRUITINGCHU de Grenoble
Grenoble, France
NOT_YET_RECRUITINGCHU de Lille
Lille, France
NOT_YET_RECRUITINGCHU de Limoges
Limoges, France
NOT_YET_RECRUITING...and 18 more locations
Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 2 years
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 3 years
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 4 years
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 5 years
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 6 years
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: Inclusion
GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 6 months
GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 3 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 4 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 5 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 6 year
GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 18 months
GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 2 years
GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
GFAP level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
GFAP level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
GFAP level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
GFAP level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
GFAP level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
GFAP level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
GFAP level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 year
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with disease activity (relapse, or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with disease activity (relapse, or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 2 years
Level of disability
Expanded Disability Status Scale (EDSS); scale 1= no disability to 10 = death from multiple sclerosis
Time frame: Inclusion
Level of disability
Expanded Disability Status Scale (EDSS); scale 1= no disability to 10 = death from multiple sclerosis
Time frame: Relapse (measured up to 2 years)
Severity of multiple sclerosis
Multiple Sclerosis Functional Composite
Time frame: EDSS progression (measured up to 2 years)
Severity of multiple sclerosis
Multiple Sclerosis Functional Composite
Time frame: Active MRI (measured up to 2 years)
Generic health status
EuroQol 5 dimension questionnaire (EQ-5D)
Time frame: Inclusion
Generic health status
EuroQol 5 dimension questionnaire (EQ-5D)
Time frame: Relapse (measured up to 2 years)
Generic health status
EuroQol 5 dimension questionnaire (EQ-5D)
Time frame: EDSS progression (measured up to 2 years)
Generic health status
EuroQol 5 dimension questionnaire (EQ-5D)
Time frame: active MRI (measured up to 2 years)
Use of Disease Modifying Drugs
Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)
Time frame: Inclusion
Use of Disease Modifying Drugs
Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)
Time frame: 6 monrths
Use of Disease Modifying Drugs
Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)
Time frame: 1 year
Use of Disease Modifying Drugs
Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)
Time frame: 18 months
Use of Disease Modifying Drugs
Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)
Time frame: 2 years
Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
pg/mL; measured by digital ELISA
Time frame: Month 6
Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
pg/mL; measured by digital ELISA
Time frame: Month 6
Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
pg/mL; measured by digital ELISA
Time frame: Month 6
Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
pg/mL; measured by digital ELISA
Time frame: Month 6
Create biobank
Blood samples
Time frame: Inclusion
Create biobank
Blood samples
Time frame: 6 months
Create biobank
Blood samples
Time frame: 1 year
Create biobank
Blood samples
Time frame: 18 months
Create biobank
Blood samples
Time frame: 2 years